Moderna retreats from 52-week high, wiping out $10 bln in value

Merck & Co

16/10/2026 16:42

** Shares of Moderna MRNA.O fall 11.6% to $209.16, snapping a three-day winning streak and worst performer on the Nasdaq 100 .NDX
** Stock on track for its biggest one-day drop since Aug 20, shedding $10 billion in market value if losses hold
** Pullback follows a 52-week high of $242.29 on Thursday and a gain of about 20% over the previous three sessions
** Shares are still up more than 50% over the past month and nearly tenfold from their 52-week low of $22.28 in November
** Rally has been driven by the late-stage cancer vaccine trial data developed with Merck MRK.N 
** Detailed data from the Moderna-Merck cancer vaccine trial is due at the ESMO Congress on October 24
** Earlier this month, Moderna joined the Nasdaq 100 index to replace Warner Bros Discovery
** 6 of 25 brokerages rate Moderna's stock "buy" or higher, 15 rate it "hold" and four rate it "sell" or lower; their median price target is $130 - LSEG
** Including session's move, MRNA up more than sevenfold YTD    


 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))